n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Wahab, O; Bewersdorf, JP; Bourcier, J; Chandhok, NS; Chaudhry, S; Derkach, A; Hogg, SJ; Lu, SX; Mi, X; Rahman, J; Stahl, M; Stein, EM; Taylor, J; Totiger, TM; Watts, J; Wysocki, M | 1 |
| de Vos, F; Dean, E; Evans, TR; Flynn, M; Greystoke, A; Kristeleit, R; Lolkema, MP; Megui-Roelvink, M; Milojkovic Kerklaan, B; Ottesen, L; Plummer, R; Ranson, M; Reyderman, L; Schellens, JH; Slater, S; Witteveen, PO | 1 |
| Colombo, L; Paolillo, M; Russo, MA; Schinelli, S; Serra, M | 1 |
| Giles, FJ; Hook, L; Kelly, KR; Krivelevich, I; Mita, A; Mita, M; Okereke, C; Ricart, AD; Romero, O; Rossignol, DP; Rowinsky, EK; Takimoto, C; Tolcher, A | 1 |
| Beijnen, JH; Funahashi, Y; Huitema, AD; Keizer, RJ; Schellens, JH; Semba, T; Wanders, J | 1 |
| Semba, T | 1 |
| Tucker, GC | 1 |
3 review(s) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Neoplasms
| Article | Year |
|---|---|
Small molecule integrin antagonists in cancer therapy.
Topics: Anoikis; Humans; Indoles; Integrin alphaVbeta3; Integrins; Neoplasms; Peptides; Receptors, Vitronectin; Signal Transduction; Snake Venoms; Sulfonamides | 2009 |
[Current status of combination therapies of angiogenesis inhibitors: vascular normalization activity of a novel angiogenesis inhibitor E7820].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Fibroblast Growth Factors; Humans; Indoles; Integrin alpha2; Mice; Molecular Targeted Therapy; Neoplasms; Sulfonamides; Vascular Endothelial Growth Factor A | 2013 |
Integrins: molecular targets in cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Indoles; Integrins; Melanoma; Neoplasms; Porphyrins; Skin Neoplasms; Snake Venoms; Sulfonamides | 2006 |
4 trial(s) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Neoplasms
| Article | Year |
|---|---|
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
Topics: Humans; Indoles; Neoplasms; RNA Splicing; RNA Splicing Factors; Sulfonamides | 2023 |
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Food-Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Indoles; Integrin alpha2; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; RNA, Messenger; Sulfonamides; Treatment Outcome | 2016 |
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoles; Integrin alpha2; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2011 |
Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indoles; Integrin alpha2; Male; Mice; Mice, Nude; Middle Aged; Models, Biological; Neoplasm Transplantation; Neoplasms; Nonlinear Dynamics; Pancreatic Neoplasms; Sulfonamides; Treatment Outcome | 2011 |